The Lancet RSS feed. https://www.thelancet.com/journals/lancet/issue/current Elsevier Limited en © 2026 Elsevier Limited The Lancet 0140-6736 2026-06-11-07:00 Copyright © 2026 Elsevier Limited permissionshelpdesk@elsevier.com 407 10546 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01183-9/fulltext?rss=yes Chronic kidney disease (CKD) has emerged after decades of neglect, we noted in November 2025, with the adoption of the WHO resolution on kidney health. The resolution was a long overdue recognition of the need for concerted global attention. However, efforts to implement and operationalise these kinds of agreements are often met with opposition, inertia, and indifference. A Health Policy paper in this week's issue of The Lancet provides practical guidance on how to fulfil the resolution's promises, drawing on lessons from diabetes control and calling for integration in the broader non-communicable disease agenda. The next steps for chronic kidney disease The Lancet 10.1016/S0140-6736(26)01183-9 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Editorial 2345 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01093-7/fulltext?rss=yes The 2026 epidemic of Ebola virus disease caused by Bundibugyo virus (species Orthoebolavirus bundibugyoense) in DR Congo and Uganda has been declared a public health emergency of international concern by WHO1 and a public health emergency of continental security by the Africa Centres for Disease Control and Prevention (CDC).2 By May 23, 2026, there had been 91 laboratory-confirmed cases, 867 suspected cases, and 214 deaths (ten laboratory confirmed) in DR Congo, and five cases and one death as imported cases in Uganda. Urgent need for a reliable rapid diagnostic test for the Ebola epidemic caused by Bundibugyo virus in Africa Safura Abdool Karim, Sharana Mahomed, Lara Lewis, Salim S Abdool Karim 10.1016/S0140-6736(26)01093-7 The Lancet 407, 10546 (2026) 2026-06-02T22:30:00Z The Lancet 2026-06-02T22:30:00Z 407 10546 S0140-6736(26)X2021-9 Comment 2346 2348 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01091-3/fulltext?rss=yes Chronic kidney disease (CKD) causes one death every 20 seconds.1 CKD ranks among the fastest growing global causes of death, forecast to become the fifth most common cause of death by 2040. Type 2 diabetes is a common cause of CKD progressing to kidney failure. However, over 50% of incident kidney failure requiring kidney replacement therapy is due to other causes. Diabetes only ranks fourth among prevalent kidney replacement therapy causes in Europe, after glomerular diseases, inherited kidney diseases, and unknown cause. Finerenone: kidney protection beyond type 2 diabetes Alberto Ortiz, Beatriz Fernandez-Fernandez 10.1016/S0140-6736(26)01091-3 The Lancet 407, 10546 (2026) 2026-06-05T10:45:00Z The Lancet 2026-06-05T10:45:00Z 407 10546 S0140-6736(26)X2021-9 Comment 2348 2350 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01094-9/fulltext?rss=yes Endothelin biology remains an attractive therapeutic target in IgA nephropathy where intrarenal endothelin-1 expression is upregulated and implicated in nephron loss through vasoconstriction, mesangial cell proliferation, inflammation, apoptosis and fibrosis.1 This mechanistic rationale has driven renewed interest in endothelin receptor A (ETA) antagonists (ERAs) across chronic kidney disease, including IgA nephropathy.2 Endothelin antagonism in IgA nephropathy: promise ahead of proof? Peter-Joon Lee, Muh Geot Wong 10.1016/S0140-6736(26)01094-9 The Lancet 407, 10546 (2026) 2026-06-04T10:15:01Z The Lancet 2026-06-04T10:15:01Z 407 10546 S0140-6736(26)X2021-9 Comment 2350 2352 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01136-0/fulltext?rss=yes GLP-1 receptor agonists have revolutionised the care of people with type 2 diabetes and obesity, because they are highly effective for glycaemic control and chronic weight management while delivering improved cardiovascular and kidney outcomes.1,2 Building on the success of single GLP-1 receptor agonism, it is hoped that modulation of additional nutrient-stimulated hormone receptors will deliver better value through greater efficacy, broader metabolic benefits, or improved tolerability. Indeed, tirzepatide (at doses of 5 mg, 10 mg, or 15 mg), a unimolecular dual agonist of both GLP-1 and gastric inhibitory polypeptide (GIP) receptors, induces greater improvements in glycated haemoglobin (HbA1c) and weight than the GLP-1 receptor agonist semaglutide (1 mg) in people with type 2 diabetes. Multireceptor modulation in metabolic disease: are more targets better? Shuyao Zhang, Ildiko Lingvay 10.1016/S0140-6736(26)01136-0 The Lancet 407, 10546 (2026) 2026-06-06T18:30:01Z The Lancet 2026-06-06T18:30:01Z 407 10546 S0140-6736(26)X2021-9 Comment 2352 2354 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00982-7/fulltext?rss=yes In The Lancet in 1971, Julian Tudor Hart gave medicine one of its most important insights: the availability of medical care tends to vary inversely with need—the inverse care law.1 Half a century later, artificial intelligence (AI) risks turning this observation into something more dynamic and dangerous. Evidence suggests that AI implementation is already unevenly distributed. In a 2023–24 analysis of 3560 US hospitals, implementation of AI models was geographically clustered, and regions with greater health-care need were less likely to have hospitals using such systems. The recursive care law: artificial intelligence reinforcing feedback loops and health inequity Josip Car, Tien Yin Wong, Rifat Atun 10.1016/S0140-6736(26)00982-7 The Lancet 407, 10546 (2026) 2026-05-22T22:30:01Z The Lancet 2026-05-22T22:30:01Z 407 10546 S0140-6736(26)X2021-9 Comment 2354 2356 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01142-6/fulltext?rss=yes The Lancet's annual Highlights photography competition began in 2009; since then we have published photographs that capture a rich variety of health stories worldwide. In 2025 some of the winning images came from China, India, Kenya, Japan, Mali, Nepal, South Africa, South Korea, The Gambia, the USA, and Zimbabwe.1 Highlights 2026 is now open for submissions. Highlights 2026 photography competition: health and humanity in focus Joanna Palmer 10.1016/S0140-6736(26)01142-6 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Comment 2356 2357 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00919-0/fulltext?rss=yes “In medicine, needless to say, the moment you feel as if you've mastered something is invariably the point at which your next experience will knock you straight back down to earth.”1 Physician and writer Rachel Clarke's words will ring true, painfully so, with anyone in practice, but especially early-career clinicians. Doctors emerge proudly from final examinations and assessments, brains overflowing with facts and figures, only to realise that the real process of learning has only just begun. For this year's Wakley Prize, we're interested in the early years of a health professional's career. The Wakley Prize 2026: learning experience Niall Boyce, Chloe Wilson, Joanna Palmer, Maneet Virdi, Madeleine Clarke, Claire Lenahan, Electra Way, Kate Wilcock 10.1016/S0140-6736(26)00919-0 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Comment 2357 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01184-0/fulltext?rss=yes The organisations’ announcement promises a unified coordinated response to controlling the Bundibugyo Ebola virus outbreak. John Zarocostas reports. WHO and Africa CDC launch $518 million Ebola plan John Zarocostas 10.1016/S0140-6736(26)01184-0 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 World Report 2358 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01185-2/fulltext?rss=yes Critics are calling for the IMA to be suspended from the World Medical Association over its stance on Gaza. Udani Samarasekera reports. Petition calls for boycott of Israeli Medical Association Udani Samarasekera 10.1016/S0140-6736(26)01185-2 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 World Report 2359 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01186-4/fulltext?rss=yes Although the hantavirus outbreak on MV Hondius has drawn the world's attention, day-to-day practice is usually a little more prosaic. Talha Burki embarks on an examination of cruise ships. The medicine of…cruise ships Talha Burki 10.1016/S0140-6736(26)01186-4 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 World Report 2360 2361 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01151-7/fulltext?rss=yes At times of stress, we are often told to do less. But a crammed diary has always been a cue for me to do more: snatch time to read, pick up a pen, paint with my daughter. These activities soothe and stretch my brain in ways I can’t find otherwise, although I have never thought of them as contributions to my health; rather, part of how I live. It is concerning that doctors are less likely than the general population to engage in the arts because evidence has long highlighted their empathy-enhancing potential. Art on repeat prescription Kate Womersley 10.1016/S0140-6736(26)01151-7 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Perspectives 2362 2363 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01150-5/fulltext?rss=yes I am sitting in my office in Montpellier, France, between two consultations, when I glance at my phone and see the notifications accumulating: images of buildings reduced to dust, familiar streets rendered unrecognisable, places I know by heart. Beirut, my home city, is being bombarded again. A few minutes later, I begin a new consultation with a patient, listen, assess, and organise a treatment plan. Outwardly, nothing has changed. And yet, something within me has shifted, in a way that resonates with processes I recognise clinically: a subtle activation of threat-related vigilance and emotional memory. Between two worlds: war, memory, and what resists within Hala Kerbage 10.1016/S0140-6736(26)01150-5 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Perspectives 2364 2365 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01149-9/fulltext?rss=yes Geneticist and entrepreneur who sequenced the first microbial genome and set up a commercial rival to the Human Genome Project. Born in Salt Lake City, UT, USA, on Oct 14, 1946, he died of cancer on April 29, 2026, in San Diego, CA, USA, aged 79 years. J Craig Venter Georgina Ferry 10.1016/S0140-6736(26)01149-9 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Obituary 2366 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01072-X/fulltext?rss=yes On May 15, 2026, the Ministry of Public Health, Hygiene and Social Welfare of the Democratic Republic of the Congo declared a new Ebola virus disease outbreak in Ituri Province, affecting three health zones: Rwampara, Mongbwalu, and Bunia.1 Laboratory analysis confirmed the presence of Bundibugyo virus (Orthoebolavirus bundibugyoense). This outbreak is the 17th Ebola virus disease outbreak and the second Bundibugyo virus disease outbreak in the country's history. The first recognised Bundibugyo virus disease outbreak occurred in 2007–08 in Bundibugyo district, western Uganda, and the second in 2012 in Isiro, the capital of what is now Haut-Uele Province, Democratic Republic of the Congo. Bundibugyo virus disease outbreak in Ituri, Democratic Republic of the Congo Dieudonne Mwamba, Pierre Akilimali, Franck Mboussou, Francis Kabasubabo, Karl Angendu, Christian Ngandu, Richard Fotsing, Anne Ancia, Roger Samuel Kamba 10.1016/S0140-6736(26)01072-X The Lancet 407, 10546 (2026) 2026-05-29T07:41:33Z The Lancet 2026-05-29T07:41:33Z 407 10546 S0140-6736(26)X2021-9 Correspondence 2367 2369 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01042-1/fulltext?rss=yes The declaration of the 17th Ebola virus disease outbreak in the Democratic Republic of the Congo and its potential expansion into Uganda warrant urgent global attention.1 This resurgence occurs within a fragile local ecosystem characterised by chronic insecurity, mass population displacement, and severely constrained diagnostic capacities. Preliminary epidemiological data link this outbreak to a non-Zaire orthoebolavirus genotype, likely Bundibugyo virus (Orthoebolavirus bundibugyoense).2 Although Bundibugyo virus has historically been associated with a lower case fatality rate (14–63%) than Zaire ebolavirus (63–87%),3 field observations paradoxically indicate an alarmingly high mortality rate, with more than 90 suspected deaths already recorded as of May 18, 2026. The 17th Ebola outbreak in the Democratic Republic of the Congo: a syndemic challenge Serge Tonen-Wolyec, Laurent Bélec 10.1016/S0140-6736(26)01042-1 The Lancet 407, 10546 (2026) 2026-05-29T07:41:33Z The Lancet 2026-05-29T07:41:33Z 407 10546 S0140-6736(26)X2021-9 Correspondence 2369 2370 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01043-3/fulltext?rss=yes WHO's declaration of the Ebola virus disease outbreak caused by Bundibugyo virus (Orthoebolavirus bundibugyoense) in the Democratic Republic of the Congo and Uganda as a Public Health Emergency of International Concern has renewed calls for travel restrictions and border closures.1 Travel restrictions and Ebola outbreaks: public health implications Damien C Tully 10.1016/S0140-6736(26)01043-3 The Lancet 407, 10546 (2026) 2026-05-29T07:41:33Z The Lancet 2026-05-29T07:41:33Z 407 10546 S0140-6736(26)X2021-9 Correspondence 2370 2371 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01041-X/fulltext?rss=yes The newly declared outbreak of Ebola virus disease caused by Bundibugyo virus in DR Congo and Uganda once again exposes the fragility of epidemic preparedness across sub-Saharan Africa.1 As of May 15, 2026, a total of 246 suspected cases and 80 deaths (including four deaths among confirmed cases) had been reported in Ituri, DR Congo, with imported cases confirmed in Kampala, Uganda, prompting WHO to declare a Public Health Emergency of International Concern.1,2 WHO estimates previous case fatality rates between 30% and 50%, while the current outbreak has already shown alarming transmission among health-care workers and communities. Ebola outbreaks in DR Congo and Uganda: until when? Mauer Alexandre da Ascensão Gonçalves, Carlos Victor Montefusco-Pereira, Howard Lopes Ribeiro Junior 10.1016/S0140-6736(26)01041-X The Lancet 407, 10546 (2026) 2026-05-29T07:41:33Z The Lancet 2026-05-29T07:41:33Z 407 10546 S0140-6736(26)X2021-9 Correspondence 2371 2372 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00850-0/fulltext?rss=yes With great interest we read the recent meta-analysis by the Cholesterol Treatment Trialists’ (CTT) Collaboration, which provides reassuring evidence regarding common safety concerns associated with statin therapy, using individual participant data from large double-blind trials.1 Challenges in assessing statin-associated adverse events Marte F van der Bijl, Ruben J M Mijnster, P Hugo M van der Kuy, Melvin Lafeber, Jeanine E Roeters van Lennep 10.1016/S0140-6736(26)00850-0 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Correspondence 2372 2373 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00855-X/fulltext?rss=yes The Cholesterol Treatment Trialists’ (CTT) Collaboration report an individual participant data meta-analysis of double-blind randomised controlled trials (RCTs) assessing whether adverse outcomes listed in statin product labels are causally attributable to statin therapy.1 Their analysis, aimed at controlling the false discovery rate at 5%, concluded that the data do not support causal relationships between statin therapy and most labelled conditions listed on product labels as potential undesirable effects. Challenges in assessing statin-associated adverse events Alessandro Rovetta, Steven D Stovitz, Leonardo Biscetti, Mohammad Ali Mansournia 10.1016/S0140-6736(26)00855-X The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Correspondence 2373 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01147-5/fulltext?rss=yes We thank Marte F van der Bijl and colleagues and Alessandro Rovetta and colleagues for their interest in our Article.1 Using data from 123 940 participants in 19 double-blind randomised trials of a statin versus placebo, we assessed the evidence base for claims of treatment-related adverse effects currently listed in statin product labels. For the vast majority of such outcomes, we found no evidence that they were increased (or decreased) by statin therapy. Consequently, we concluded that these trial data do not support causal relationships between statin therapy and most of the conditions listed in product labels as potential adverse effects. Challenges in assessing statin-associated adverse events – Authors’ reply Christina Reith, Jonathan R Emberson, David Preiss, Rory Collins, Colin Baigent, Cholesterol Treatment Trialists’ (CTT) Collaboration 10.1016/S0140-6736(26)01147-5 The Lancet 407, 10546 (2026) 2026-06-13 The Lancet 2026-06-13 407 10546 S0140-6736(26)X2021-9 Correspondence 2373 2374 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01012-3/fulltext?rss=yes Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials. Lancet 2026; 407: 1699–711—In this Article, figure 2 and figure 3 have been updated. This correction has been made to the online version as of May 19, 2026. Department of Error 10.1016/S0140-6736(26)01012-3 The Lancet 407, 10546 (2026) 2026-05-19T22:30:01Z The Lancet 2026-05-19T22:30:01Z 407 10546 S0140-6736(26)X2021-9 Department of Error 2374 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01009-3/fulltext?rss=yes In the studied populations with CKD, finerenone reduced the risk of CKD progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death. These findings support finerenone as a foundational therapy for CKD across a broad range of disease aetiologies and levels of glycaemia, eGFR, and albuminuria. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY) Brendon L Neuen, Hiddo J L Heerspink, Vlado Perkovic, David Z I Cherney, Carolyn S P Lam, Katherine R Tuttle, Christoph Wanner, Pantelis Sarafidis, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis M Ruilope, Niels Jongs, J David Smeijer, Meike Brinker, Christiane Ahlers, Andrea Lage, Andrea Horvat-Bröcker, Patrick Schloemer, Thomas Eissing, Rania Dayoub, Robert Lawatscheck, Rajiv Agarwal, FIND-CKD, FIDELIO-DKD and FIGARO-DKD Investigators 10.1016/S0140-6736(26)01009-3 The Lancet 407, 10546 (2026) 2026-06-05T10:45:01Z The Lancet 2026-06-05T10:45:01Z 407 10546 S0140-6736(26)X2021-9 Articles 2375 2386 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00960-8/fulltext?rss=yes Atrasentan reduced proteinuria and preserved kidney function after 2·5 years. This effect was present with or without concomitant SGLT2 inhibitor use. Atrasentan was well tolerated. Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial Hiddo J L Heerspink, Meg J Jardine, Donald E Kohan, Richard Lafayette, Adeera Levin, Adrian Liew, Hong Zhang, Irene L Noronha, Gianna Mastroianni-Kirsztajn, Stephen Chow, Dae Eun Choi, Jicheng Lv, Hernán Trimarchi, Ping Fu, Siegbert Guenther, Shuping Yang, Junhao Liu, Swapna Rahalkar, Amit Lodha, Marion Dahlke, Dmitrij Kollins, Jonathan Barratt, ALIGN study group 10.1016/S0140-6736(26)00960-8 The Lancet 407, 10546 (2026) 2026-06-04T10:15:01Z The Lancet 2026-06-04T10:15:01Z 407 10546 S0140-6736(26)X2021-9 Articles 2387 2401 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00967-0/fulltext?rss=yes Retatrutide showed significant improvements in glycaemic control and bodyweight reduction as a monotherapy in adults with type 2 diabetes that is inadequately controlled with diet and exercise alone, with an adverse event profile consistent with molecules with GLP-1 agonist activity, supporting its potential as an effective treatment for type 2 diabetes. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial Harpreet S Bajaj, Michelle Welch, Parag Shah, Eduardo Luna, Fatima-Zahra Jaouimaa, Bing Liu, Rong Liu, Yanyun Chen, Hiren Patel, Amy Bartee 10.1016/S0140-6736(26)00967-0 The Lancet 407, 10546 (2026) 2026-06-06T18:30:01Z The Lancet 2026-06-06T18:30:01Z 407 10546 S0140-6736(26)X2021-9 Articles 2402 2413 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00702-6/fulltext?rss=yes Chronic kidney disease affects 788–844 million adults worldwide and is projected to become the fifth leading cause of death by 2040. Global burden estimates remain limited by ascertainment bias and inadequate access to testing, particularly in low-income and middle-income countries. Advances in detection include improved estimation of glomerular filtration rate (GFR) using cystatin C and the recognition of albuminuria as a key marker for screening and risk stratification. Kidney biopsy is improving diagnostic accuracy and prognostic prediction, and multiomics approaches are advancing our understanding of disease mechanisms and hold promise for precision medicine. Advances in the diagnosis and detection of chronic kidney disease Jennifer S Lees, Luxia Zhang, Urmila Anandh, Andreas Kronbichler, Lori-Ann Fisher, Matthew Borg, Angela Y Wang, Adeera Levin 10.1016/S0140-6736(26)00702-6 The Lancet 407, 10546 (2026) 2026-06-03T07:30:01Z The Lancet 2026-06-03T07:30:01Z 407 10546 S0140-6736(26)X2021-9 Series 2414 2428 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00654-9/fulltext?rss=yes Biological differences exist between males and females in kidney structure and function, leading to sex heterogeneity in the presentation and outcomes of chronic kidney disease (CKD) and response to novel therapeutics. However, treatment guidelines ignore sex-specific differences. This Series paper provides an integrated discussion of the complexity of sex differences in the context of kidney health and disease, from biology through clinical characteristics, treatment, evidence generation, and reporting. Advances in understanding the impact of sex on kidney health and disease Jennifer S Lees, Kate I Stevens, Sradha S Kotwal, Annette Bruchfeld, Adeera Levin 10.1016/S0140-6736(26)00654-9 The Lancet 407, 10546 (2026) 2026-06-03T07:30:01Z The Lancet 2026-06-03T07:30:01Z 407 10546 S0140-6736(26)X2021-9 Series 2429 2443 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00653-7/fulltext?rss=yes Chronic kidney disease (CKD) is increasingly recognised as a complex, multisystem condition that rarely occurs in isolation. This Series paper outlines major advances in therapeutics that target shared inflammatory, metabolic, and fibrotic pathways across CKD, cardiovascular disease, diabetes, obesity, and infection. Novel therapeutics, including SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP receptor agonists, show substantial benefits for slowing CKD progression and improving cardiovascular outcomes, with combination strategies showing additive potential. Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges Jennifer S Lees, Andrej Škoberne, Luxia Zhang, Christina Wyatt, June Fabian, Angela Y Wang, Louise Oni, Adeera Levin 10.1016/S0140-6736(26)00653-7 The Lancet 407, 10546 (2026) 2026-06-03T07:30:01Z The Lancet 2026-06-03T07:30:01Z 407 10546 S0140-6736(26)X2021-9 Series 2444 2460 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00755-5/fulltext?rss=yes Chronic kidney disease affects 850 million people worldwide and places a disproportionate burden on low-income and middle-income countries where access to timely diagnosis, treatment, and life-sustaining kidney replacement therapy (KRT) is restricted. In May, 2025, the 78th World Health Assembly adopted a resolution on kidney health that called on all member states to integrate kidney care into national strategies; enhance prevention, early detection, and timely management; strengthen primary care; expand access to KRT; and enhance capacity for measuring burden, progress, and return on investment. Implementing the commitments of the World Health Assembly kidney health resolution: a key opportunity to improve health for millions Marcello Tonelli, Robert Kalyesubula, Somkanya Tungsanga, Anna Francis, John Gill, Randall Lou-Meda, Valerie Luyckx, Aminu Bello 10.1016/S0140-6736(26)00755-5 The Lancet 407, 10546 (2026) 2026-05-19T22:30:01Z The Lancet 2026-05-19T22:30:01Z 407 10546 S0140-6736(26)X2021-9 Health Policy 2461 2472